Full-Time

Manager International Business

Sarepta

Sarepta

1,001-5,000 employees

Develops gene therapies for rare diseases

No salary listed

No H1B Sponsorship

Cambridge, MA, USA

Hybrid

Hybrid work requires on-site attendance at a Sarepta facility in the United States and/or attendance at company-sponsored in-person events from time to time.

Bachelor's

Category
Business & Strategy (1)

Get referred to Sarepta

See people who can refer or advise you

Requirements
  • A Bachelor's degree in general business, health sciences, public policy, or another related degree is required.
  • At least 5 years of pharmaceutical or healthcare-related experience are required.
  • Strong project coordination and administration skills are required.
  • Leadership skills and experience are required.
  • The candidate must be detail-oriented and highly organized.
  • The candidate must be able to multitask in a fast-paced environment.
  • Strong listening, verbal, and written communication skills are required.
  • The candidate must be team-oriented and willing to collaborate.
  • The candidate must have leadership, people-management, influencing, and motivating skills and the ability to manage complexity requiring both strategic and tactical skills.
  • The candidate must be authorized to work in the United States.
Responsibilities
  • Build on Sarepta’s vision to help physicians and families access Sarepta’s medications outside the United States.
  • Manage International Business meetings, including developing, managing, and facilitating agendas and meetings; preparing concise meeting minutes; and capturing and following up on action items in a timely manner.
  • Manage operational aspects of the International Business team, including systems and reporting outputs.
  • Manage the tracking tool by product and ongoing status in outside-United-States countries to provide relevant updates to stakeholders.
  • Create project plans for new product and outside-United-States country launches and manage coordination, execution, and integration with all partners.
  • Work closely within International Business with Global Access and Patient Services teams.
  • Provide tactical oversight while managing and collaborating with external vendors, partners, and consultants on outside-United-States-related efforts.
  • Help coordinate contracting within the department, ensuring amendments and updates are tracked appropriately, and partner with the procurement team.
  • Act in complete compliance with all laws, regulations, and Sarepta policy.
  • Perform other related duties as needed.

Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1980

Get referred to Sarepta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted AMONDYS 45 and VYONDYS 53 conversion filings, with February 28, 2027 PDUFA.
  • First-quarter 2026 revenue reached $730.8 million, beating estimates despite Elevidys decline.
  • 2025 restructuring cuts 500 jobs and targets $400 million annual savings starting 2026.

What critics are saying

  • FDA revoked Sarepta's AAVrh74 platform designation after July 18, 2025 liver-failure deaths.
  • The March 2026 securities class action over Elevidys disclosures is still ongoing.
  • Elevidys label restrictions and shipment disruptions threaten Sarepta's core revenue before 2027.

What makes Sarepta unique

  • Elevidys remains the only U.S. approved gene therapy for Duchenne muscular dystrophy.
  • AMONDYS 45 and VYONDYS 53 anchor a proprietary PMO exon-skipping franchise.
  • Michael Severino joined July 28, 2026, bringing AbbVie R&D and Tessera gene-editing experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Jul 28th, 2026
Legend Biotech CEO abruptly resigns as Sarepta appoints ex-AbbVie president

Legend Biotech's CEO Ying Huang resigned abruptly on 24 July, with the company stating his departure was not due to any disagreement. Alan Bash, president of Legend's Carvykti Business Unit, will serve as interim CEO whilst a search for a permanent replacement is underway. Separately, Sarepta Therapeutics appointed Michael Severino as its new CEO following a five-month search. Severino, formerly president of AbbVie and CEO of Tessera Therapeutics, brings over 25 years of biopharma experience. He replaces Doug Ingram, who announced his retirement in February for personal reasons. The leadership changes come as Legend faces competition for its blockbuster CAR-T therapy Carvykti, whilst Sarepta recently implemented a 36% workforce reduction amid challenges with its DMD gene therapy Elevidys.

Associated Press
Jul 27th, 2026
Sarepta Therapeutics appoints AbbVie veteran Michael Severino as chief executive officer

Sarepta Therapeutics has appointed Michael Severino as chief executive officer, effective 28 July 2026. Severino, who will also join the board of directors, brings over 25 years of biopharmaceutical experience to the Cambridge-based precision genetic medicine company. Severino previously served as CEO of Tessera Therapeutics and held senior positions at AbbVie, where he was vice chairman and president responsible for research and development. At AbbVie, he oversaw pipeline expansion and contributed to more than a dozen approved therapies. He succeeds Doug Ingram, who is retiring after leading Sarepta through significant growth, including approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy. Ingram will serve in an advisory capacity until the end of 2026.

Yahoo Finance
Jul 14th, 2026
Sarepta's DMD therapies move closer to full FDA approval with sNDA acceptance

Sarepta Therapeutics announced the FDA has accepted supplemental New Drug Applications to convert accelerated approvals for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 to traditional approvals. The PDUFA action date is set for 28 February 2027. The applications are supported by the ESSENCE confirmatory study and real-world evidence from over 1,800 treated patients. This could strengthen the regulatory foundation of Sarepta's exon-skipping franchise. The development may help diversify Sarepta's regulatory position in DMD treatment, potentially offsetting concentration risk around its ELEVIDYS therapy. ELEVIDYS recently received an FDA boxed warning for acute liver injury in November 2025. Sarepta's narrative projects $1.4 billion revenue and $87.3 million earnings by 2029, requiring a 13.3% yearly revenue decline from current levels.

Yahoo Finance
May 14th, 2026
Sarepta Therapeutics' profit boosted by $52M unusual items amid 7.4% share dilution

Sarepta Therapeutics reported statutory profits that disappointed investors, with underlying concerns emerging from the earnings analysis. The company increased its share count by 7.4% over the past year, diluting per-share returns despite generating net income. The biotechnology firm was unprofitable three years ago and last year, making year-on-year growth comparisons difficult. Whilst the company achieved profit over the last 12 months, earnings per share would have been stronger without the share dilution. Additionally, Sarepta's profit received a significant boost from unusual items worth $52 million in the last 12 months. These one-off contributions may make statutory profit a poor indicator of underlying earnings power. The combination of share dilution and unusual items raises questions about the sustainability of the company's reported profitability.

Yahoo Finance
May 6th, 2026
Sarepta Therapeutics reports $731M revenue, beats estimates by 56% with $3.16 EPS in Q1

Sarepta Therapeutics reported Q1 2026 revenue of $730.8 million, down 1.9% year-over-year, but exceeding the consensus estimate of $467.85 million by 56.2%. The biotechnology company posted earnings per share of $3.16, compared to a loss of $3.42 in the prior-year quarter, surpassing the consensus estimate of $0.90 by 253%. Product revenue totalled $330.52 million, slightly above analyst estimates of $325.88 million, representing a 46% year-over-year decline. PMO Products generated $228.55 million, whilst ELEVIDYS contributed $101.97 million, exceeding expectations despite a 72.8% year-over-year decrease. Shares have fallen 5.6% over the past month. The stock currently holds a Zacks Rank of Hold.